LEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation

Deep News01-30

LEADS BIOLABS-B (09887) saw its share price climb 8.78% in the afternoon session, currently trading at HKD 65.65, with a turnover of HKD 52.8146 million.

The company announced that on January 27th, its GPRC5D/CD3 bispecific antibody, LBL-034, which features a unique 2:1 structure and conditional activation and was self-developed based on the TCE technology platform LeadsBody, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma.

Huafu Securities released a research report stating that LEADS BIOLABS is comprehensively developing next-generation tumor immunotherapy based on its agonist platform, TCE platform, and ADC technology. From the X-body platform in 2015 and the LeadsBody platform in 2016, to subsequent accumulations in bispecific and trispecific antibody technologies, the company has consistently focused on a "technology platform + innovative targets" core strategy, covering cutting-edge areas such as immune checkpoints and multi-specific antibodies, thereby building a differentiated pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151736923?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 14:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151736923","market":"nz","top_or_hot":-1,"title":"LEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation","media":"Deep News","content":"<p>LEADS BIOLABS-B (09887) saw its share price climb 8.78% in the afternoon session, currently trading at HKD 65.65, with a turnover of HKD 52.8146 million.</p>\n<p>The company announced that on January 27th, its GPRC5D/CD3 bispecific antibody, LBL-034, which features a unique 2:1 structure and conditional activation and was self-developed based on the TCE technology platform LeadsBody, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma.</p>\n<p>Huafu Securities released a research report stating that LEADS BIOLABS is comprehensively developing next-generation tumor immunotherapy based on its agonist platform, TCE platform, and ADC technology. From the X-body platform in 2015 and the LeadsBody platform in 2016, to subsequent accumulations in bispecific and trispecific antibody technologies, the company has consistently focused on a \"technology platform + innovative targets\" core strategy, covering cutting-edge areas such as immune checkpoints and multi-specific antibodies, thereby building a differentiated pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-30 14:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) saw its share price climb 8.78% in the afternoon session, currently trading at HKD 65.65, with a turnover of HKD 52.8146 million.</p>\n<p>The company announced that on January 27th, its GPRC5D/CD3 bispecific antibody, LBL-034, which features a unique 2:1 structure and conditional activation and was self-developed based on the TCE technology platform LeadsBody, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma.</p>\n<p>Huafu Securities released a research report stating that LEADS BIOLABS is comprehensively developing next-generation tumor immunotherapy based on its agonist platform, TCE platform, and ADC technology. From the X-body platform in 2015 and the LeadsBody platform in 2016, to subsequent accumulations in bispecific and trispecific antibody technologies, the company has consistently focused on a \"technology platform + innovative targets\" core strategy, covering cutting-edge areas such as immune checkpoints and multi-specific antibodies, thereby building a differentiated pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1151736923","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151736923","pubTimestamp":1769754137,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"LEADS BIOLABS-B (09887) saw its share price climb 8.78% in the afternoon session, currently trading at HKD 65.65, with a turnover of HKD 52.8146 million. The company announced that on January 27th,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","09887":"维立志博-B"},"translate_title":"随着TCE双特异性抗体LBL-034获得FDA快速通道指定，LEADS BIOLABS-B在下午交易中飙升超过9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B (09887) saw its share price climb 8.78% in the afternoon session, currently trading at HKD 65.65, with a turnover of HKD 52.8146 million.\nThe company announced that on January 27th, its GPRC5D/CD3 bispecific antibody, LBL-034, which features a unique 2:1 structure and conditional activation and was self-developed based on the TCE technology platform LeadsBody, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma.\nHuafu Securities released a research report stating that LEADS BIOLABS is comprehensively developing next-generation tumor immunotherapy based on its agonist platform, TCE platform, and ADC technology. From the X-body platform in 2015 and the LeadsBody platform in 2016, to subsequent accumulations in bispecific and trispecific antibody technologies, the company has consistently focused on a \"technology platform + innovative targets\" core strategy, covering cutting-edge areas such as immune checkpoints and multi-specific antibodies, thereby building a differentiated pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151736923","isCrawlerRequest":true}